NeoGenomics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
NeoGenomics, Inc. (NEO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2018-03-13
- NeoGenomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was $0.00.
- NeoGenomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- NeoGenomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $2.24M, a 1187.82% increase from fiscal 2014.
- NeoGenomics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was $174.00K, a 68.48% decline from fiscal 2013.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-13 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-13 | |
| 2015-12-31 | $2.24M 10-K · filed 2018-03-13 | |
| 2014-12-31 | $174.00K 10-K · filed 2017-03-14 | |
| 2013-12-31 | $552.00K 10-K · filed 2016-04-18 | $560.00K 10-K · filed 2014-02-24 |
| 2012-12-31 | $1.00M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |